Comparison of Humira biosimilars in the US and Europe
The US biosimilars market is notably underdeveloped and biosimilar entry in the US has been difficult, consistently lagging behind Europe.

The US biosimilars market is notably underdeveloped and biosimilar entry in the US has been difficult, consistently lagging behind Europe.
CSPC Pharmaceutical’s SYS6006 has been designed to target some major Omicron variants.
The company reported an organic sales increase of 8.2% to €10.38bn in its Life Science business during the year.
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Risk of venous thromboembolism in Covid-19 outpatients found to be low
InvisiShield and Gladstone partner to develop intranasal preventatives
Talem and Libera Bio partner for discovery of AI-driven antibodies
One Medical CEO rebuts Amazon data privacy concerns